Leerink Partnrs Has Positive Estimate for BBIO Q3 Earnings

Key Points

• Leerink Partners has raised its Q3 2025 earnings estimate for BridgeBio Pharma from ($0.83) to ($0.78) per share, while the consensus estimate for the full year remains at ($3.67) per share.
• BridgeBio Pharma reported a 4999.9% revenue increase year-over-year, with revenue of $110.57 million in the last quarter, despite missing EPS estimates.
• Analyst ratings are predominantly positive, with 17 buy ratings and a price target average of $63.94, indicating strong institutional confidence in BridgeBio's future prospects.

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Research analysts at Leerink Partnrs raised their Q3 2025 earnings estimates for shares of BridgeBio Pharma in a note issued to investors on Tuesday, October 14th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($0.78) per share for the quarter, up from their prior estimate of ($0.83). The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma's Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($3.38) EPS, FY2026 earnings at ($1.11) EPS and FY2028 earnings at $4.41 EPS.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The company had revenue of $110.57 million during the quarter, compared to analysts' expectations of $98.46 million. During the same quarter last year, the firm posted ($0.39) earnings per share. BridgeBio Pharma's quarterly revenue was up 4999.9% compared to the same quarter last year.

Several other research analysts have also recently weighed in on BBIO. JPMorgan Chase & Co. raised their target price on BridgeBio Pharma from $55.00 to $70.00 and gave the company an "overweight" rating in a research note on Wednesday, September 3rd. HC Wainwright reissued a "buy" rating and issued a $70.00 price target on shares of BridgeBio Pharma in a report on Monday, September 15th. Oppenheimer boosted their target price on shares of BridgeBio Pharma from $60.00 to $61.00 and gave the stock an "outperform" rating in a report on Wednesday, August 6th. Wall Street Zen upgraded shares of BridgeBio Pharma from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Piper Sandler lifted their price target on shares of BridgeBio Pharma from $63.00 to $68.00 and gave the stock an "overweight" rating in a research report on Monday, July 14th. Seventeen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, BridgeBio Pharma presently has an average rating of "Moderate Buy" and an average target price of $63.94.

BridgeBio Pharma Stock Performance

Shares of BBIO stock opened at $56.63 on Thursday. BridgeBio Pharma has a 1 year low of $21.72 and a 1 year high of $57.49. The stock has a market cap of $10.83 billion, a PE ratio of -13.85 and a beta of 1.36. The business's fifty day moving average is $51.64 and its 200-day moving average is $43.31.

Insider Buying and Selling

In related news, CFO Thomas Trimarchi sold 42,237 shares of the company's stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $49.48, for a total transaction of $2,089,886.76. Following the transaction, the chief financial officer directly owned 421,081 shares of the company's stock, valued at approximately $20,835,087.88. The trade was a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Charles J. Homcy sold 50,000 shares of the company's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $48.00, for a total value of $2,400,000.00. Following the transaction, the director directly owned 916,674 shares in the company, valued at $44,000,352. The trade was a 5.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 597,913 shares of company stock valued at $29,034,227. 18.20% of the stock is currently owned by company insiders.

Institutional Trading of BridgeBio Pharma

Several institutional investors have recently made changes to their positions in BBIO. GAMMA Investing LLC boosted its holdings in shares of BridgeBio Pharma by 71.0% during the first quarter. GAMMA Investing LLC now owns 920 shares of the company's stock worth $32,000 after purchasing an additional 382 shares during the period. Cambridge Investment Research Advisors Inc. lifted its position in BridgeBio Pharma by 29.4% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 30,802 shares of the company's stock worth $1,065,000 after buying an additional 6,997 shares in the last quarter. Diversified Trust Co increased its stake in shares of BridgeBio Pharma by 25.3% in the first quarter. Diversified Trust Co now owns 34,866 shares of the company's stock worth $1,205,000 after acquiring an additional 7,039 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of BridgeBio Pharma in the first quarter worth $251,000. Finally, First Bank & Trust increased its stake in shares of BridgeBio Pharma by 13.7% in the first quarter. First Bank & Trust now owns 8,493 shares of the company's stock worth $294,000 after acquiring an additional 1,022 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors and hedge funds.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.